UCSF home page UCSF home page About UCSF UCSF Medical Center
UCSF navigation bar
photos

Faculty Profiles

Aaron Logan, MD, PhD
M_MED-HMON-CORE-ONCO-GEN
Assistant Professor

513 Parnassus Avenue
San Francisco, CA 94117
415-502-2110

The phone number listed above is my direct office number.


If you prefer to contact the outpatient clinic, please call 415-353-2421.


The clinic fax number is 415-353-2467.

Education and Training

Location Degree or Training Specialty Date
Stanford University Blood and Marrow Transplantation Medicine 2012
Stanford University Hematology Medicine 2009
Stanford University Internal Medicine (Internship and Residency) Clinical Investigator Pathway 2008
University of Southern California M.D. Keck School of Medicine 2006
University of Southern California Ph.D. (Molec Microbio and Immunology) Keck School of Medicine 2006
University of Cambridge, England M.Phil. History and Philosophy of Medicine 1997

Interests

acute lymphoblastic leukemia (ALL), acute myelogenous leukemia (AML), antibody-mediated conditioning, aplastic anemia, blood and marrow transplantation (BMT), chronic lymphocytic leukemia (CLL), graft versus host disease, hematology, hematopoietic stem and progenitor cell biology, hematopoietic stem cell transplantation, hemophagocytic lymphohistiocytosis (HLH), high-throughput sequencing, immune reconstitution, immunology, immunoreceptor sequencing, leukemia, lymphoma, minimal residual disease, myelodysplastic syndrome (MDS), myeloma, next generation sequencing

Featured Videos

Related Web Sites

In the News

Recent Articles (36)

Miklos D, Cutler CS, Arora M, Waller EK, Jagasia M, Pusic I, Flowers ME, Logan AC, Nakamura R, Blazar BR, Li Y, Chang S, Lal I, Dubovsky J, James DF, Styles L, Jaglowski S. Ibrutinib for chronic graft-versus-host disease after failure of prior therapy. Blood. 2017 Sep 18.

Saba J, Logan AC. Obinutuzumab-induced serum sickness following salvage therapy for chronic lymphocytic leukemia. Clin Case Rep. 2017 Jun; 5(6):891-893.

Chan ST, Logan AC. The clinical impact of cytomegalovirus infection following allogeneic hematopoietic cell transplantation: Why the quest for meaningful prophylaxis still matters. Blood Rev. 2017 May; 31(3):173-183.

Majure M, Logan AC. What the blood knows: interrogating circulating tumor DNA to predict progression of minimal residual disease in early breast cancer. Ann Transl Med. 2016 Dec; 4(24):543.

Giard JM, Decker KA, Lai JC, Gill RM, Logan AC, Fix OK. Acute Liver Failure Secondary to Hemophagocytic Lymphohistiocytosis during Pregnancy. ACG Case Rep J. 2016 Aug; 3(4):e162.

Sherbenou DW, Aftab BT, Su Y, Behrens CR, Wiita A, Logan AC, Acosta-Alvear D, Hann BC, Walter P, Shuman MA, Wu X, Atkinson JP, Wolf JL, Martin TG, Liu B. Antibody-drug conjugate targeting CD46 eliminates multiple myeloma cells. J Clin Invest. 2016 Dec 01; 126(12):4640-4653.

Ryan CE, Sahaf B, Logan AC, O'Brien S, Byrd JC, Hillmen P, Brown JR, Dyer MJ, Mato AR, Keating MJ, Jaglowski S, Clow F, Rezvani AR, Styles L, Coutre SE, Miklos DB. Ibrutinib efficacy and tolerability in patients with relapsed chronic lymphocytic leukemia following allogeneic HCT. Blood. 2016 Dec 22; 128(25):2899-2908.

Mulé MP, Mannis GN, Wood BL, Radich JP, Hwang J, Ramos NR, Andreadis C, Damon L, Logan AC, Martin TG, Hourigan CS. Multigene Measurable Residual Disease Assessment Improves Acute Myeloid Leukemia Relapse Risk Stratification in Autologous Hematopoietic Cell Transplantation. Biol Blood Marrow Transplant. 2016 Nov; 22(11):1974-1982.

Mannis GN, Martin TG, Damon LE, Andreadis C, Olin RL, Kong KA, Faham M, Hwang J, Ai WZ, Gaensler KML, Sayre PH, Wolf JL, Logan AC. Quantification of Acute Lymphoblastic Leukemia Clonotypes in Leukapheresed Peripheral Blood Progenitor Cells Predicts Relapse Risk after Autologous Hematopoietic Stem Cell Transplantation. Biol Blood Marrow Transplant. 2016 Jun; 22(6):1030-1036.

Mannis GN, Martin TG, Damon LE, Logan AC, Olin RL, Flanders MD, Ai WZ, Gaensler KM, Kaplan LD, Sayre PH, Smith CC, Wolf JL, Andreadis C. Long-term outcomes of patients with intermediate-risk acute myeloid leukemia treated with autologous hematopoietic cell transplant in first complete remission. Leuk Lymphoma. 2016 Jul; 57(7):1560-6.

Logan AC, Miklos DB. . Hematopoietic cell transplantation for chronic lymphocytic leukemia, in: Appelbaum FR, Forman SJ, Negrin RS, Antin JH (Eds). Thomas' Hematopoietic Cell Transplantation, 5th Ed, John Wiley & Sons, Ltd., Chichester, UK. 2015.

Sorenson E, McAndrew R, Patel V, Logan AC, Koo J, Levin E. Narrowband UV-B Phototherapy for Steroid-Refractory Sclerotic Chronic Cutaneous Graft-vs-Host Disease. JAMA Dermatol. 2015 Jun; 151(6):635-7.

Mannis GN, Andreadis C, Logan AC, Damon LE, Benet LZ, Ai WZ, Gaensler KM, Kaplan LD, Koplowicz YB, Linker CA, Olin RL, Sayre PH, Smith CC, Sudhindra A, Venstrom JM, Wolf JL, Martin TG. A phase I study of targeted, dose-escalated intravenous busulfan in combination with etoposide as myeloablative therapy for autologous stem cell transplantation in acute myeloid leukemia. Clin Lymphoma Myeloma Leuk. 2015 Jun; 15(6):377-83.

Logan AC, Wang Z, Alimoghaddam K, Wong RM, Lai T, Negrin RS, Grumet C, Logan BR, Zhang MJ, Spellman SR, Lee SJ, Miklos DB. ABO mismatch is associated with increased nonrelapse mortality after allogeneic hematopoietic cell transplantation. Biol Blood Marrow Transplant. 2015 Apr; 21(4):746-54.

Mannis GN, Logan AC, Leavitt AD, Yanada M, Hwang J, Olin RL, Damon LE, Andreadis C, Ai WZ, Gaensler KM, Greene CC, Gupta NK, Kaplan LD, Mahindra A, Miyazaki Y, Naoe T, Ohtake S, Sayre PH, Smith CC, Venstrom JM, Wolf JL, Caballero L, Emi N, Martin TG. Delayed hematopoietic recovery after auto-SCT in patients receiving arsenic trioxide-based therapy for acute promyelocytic leukemia: a multi-center analysis. Bone Marrow Transplant. 2015 Jan; 50(1):40-4.

Kharabi Masouleh B, Geng H, Hurtz C, Chan LN, Logan AC, Chang MS, Huang C, Swaminathan S, Sun H, Paietta E, Melnick AM, Koeffler P, Müschen M. Mechanistic rationale for targeting the unfolded protein response in pre-B acute lymphoblastic leukemia. Proc Natl Acad Sci U S A. 2014 May 27; 111(21):E2219-28.

Logan AC, Vashi N, Faham M, Carlton V, Kong K, Buño I, Zheng J, Moorhead M, Klinger M, Zhang B, Waqar A, Zehnder JL, Miklos DB. Immunoglobulin and T cell receptor gene high-throughput sequencing quantifies minimal residual disease in acute lymphoblastic leukemia and predicts post-transplantation relapse and survival. Biol Blood Marrow Transplant. 2014 Sep; 20(9):1307-13.

Logan AC, Zhang B, Narasimhan B, Carlton V, Zheng J, Moorhead M, Krampf MR, Jones CD, Waqar AN, Faham M, Zehnder JL, Miklos DB. Minimal residual disease quantification using consensus primers and high-throughput IGH sequencing predicts post-transplant relapse in chronic lymphocytic leukemia. Leukemia. 2013 Aug; 27(8):1659-65.

Dunn T, Cho M, Medeiros B, Logan A, Ungewickell A, Liedtke M. Hemophagocytic lymphohistiocytosis in pregnancy: a case report and review of treatment options. Hematology. 2012 Nov; 17(6):325-8.

Rezvani K, Brody JD, Kohrt HE, Logan AC, Advani R, Czerwinski DK, Weng WK, Negrin RS, Carlton V, Faham M, Levy R, Barrett J. Cancer vaccines and T cell therapy. Biol Blood Marrow Transplant. 2013 Jan; 19(1 Suppl):S97-S101.

Logan A, Berube C, Gotlib J. Accessory splenules in autoimmune hemolytic anemia. Am J Hematol. 2013 Feb; 88(2):156.

Logan AC, Weissman IL, Shizuru JA. The road to purified hematopoietic stem cell transplants is paved with antibodies. Curr Opin Immunol. 2012 Oct; 24(5):640-8.

Gawad C, Pepin F, Carlton VE, Klinger M, Logan AC, Miklos DB, Faham M, Dahl G, Lacayo N. Massive evolution of the immunoglobulin heavy chain locus in children with B precursor acute lymphoblastic leukemia. Blood. 2012 Nov 22; 120(22):4407-17.

Riess JW, Logan AC, Krupitskaya Y, Padda S, Clément-Duchêne C, Ganjoo K, Colevas AD, Pedro-Salcedo MS, Kuo CJ, Wakelee HA. Maintenance bevacizumab is associated with increased hemoglobin in patients with advanced, nonsquamous, non-small cell lung cancer. Cancer Invest. 2012 Mar; 30(3):231-5.

Malik UF, Dastaghyab N, Logan AC.. Acute lymphoblastic leukemia, in Clinical Decision Support: Hospital Medicine, edited by Wiese J, Auerbach A, Glasheen J, Li J. Decision Support in Medicine, LLC. Wilmington, DE. 2012.

Logan AC, Gao H, Wang C, Sahaf B, Jones CD, Marshall EL, Buño I, Armstrong R, Fire AZ, Weinberg KI, Mindrinos M, Zehnder JL, Boyd SD, Xiao W, Davis RW, Miklos DB. High-throughput VDJ sequencing for quantification of minimal residual disease in chronic lymphocytic leukemia and immune reconstitution assessment. Proc Natl Acad Sci U S A. 2011 Dec 27; 108(52):21194-9.

Yank V, Tuohy CV, Logan AC, Bravata DM, Staudenmayer K, Eisenhut R, Sundaram V, McMahon D, Olkin I, McDonald KM, Owens DK, Stafford RS. Systematic review: benefits and harms of in-hospital use of recombinant factor VIIa for off-label indications. Ann Intern Med. 2011 Apr 19; 154(8):529-40.

Logan AC, Yank V, Stafford RS. Off-label use of recombinant factor VIIa in U.S. hospitals: analysis of hospital records. Ann Intern Med. 2011 Apr 19; 154(8):516-22.

Yank V, Tuohy CV, Logan AC, Bravata DM, Staudenmayer K, Eisenhut R, Sundaram V, McMahon D, Stave CD, Zehnder JL, Olkin I, McDonald KM, Owens DK, Stafford RS.. Rockville (MD): Agency for Healthcare Research and Quality (US); 2010 May. Report No.: 10-EHC030-EF. Comparative Effectiveness of In-Hospital Use of Recombinant Factor VIIa for Off-Label Indications vs. Usual Care. 2010.

Logan AC, Goodnough LT. Recombinant factor VIIa: an assessment of evidence regarding its efficacy and safety in the off-label setting. Hematology Am Soc Hematol Educ Program. 2010; 2010:153-9.

Kohrt H, Logan A, Temmins C, Witteles R, Liedtke M, Medeiros B. Reversible high-output cardiac failure, an unusual marker of disease status in multiple myeloma. Leuk Lymphoma. 2008 Mar; 49(3):581-5.

Logan AC, Nightingale SJ, Haas DL, Cho GJ, Pepper KA, Kohn DB. Factors influencing the titer and infectivity of lentiviral vectors. Hum Gene Ther. 2004 Oct; 15(10):976-88.

Logan AC, Haas DL, Kafri T, Kohn DB. Integrated self-inactivating lentiviral vectors produce full-length genomic transcripts competent for encapsidation and integration. J Virol. 2004 Aug; 78(16):8421-36.

Haas DL, Lutzko C, Logan AC, Cho GJ, Skelton D, Jin Yu X, Pepper KA, Kohn DB. The Moloney murine leukemia virus repressor binding site represses expression in murine and human hematopoietic stem cells. J Virol. 2003 Sep; 77(17):9439-50.

Logan AC, Lutzko C, Kohn DB. Advances in lentiviral vector design for gene-modification of hematopoietic stem cells. Curr Opin Biotechnol. 2002 Oct; 13(5):429-36.

  Select data provided by UCSF Profiles, powered by CTSI at UCSF. Learn more about the data source.